# Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct06558227/  
OnCo record `nct06558227` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bevacizumab, Sintilimab in hepatocellular carcinoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT06558227 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 90 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-09. Interventions recorded: ZG005 for Injection, Bevacizumab, Sintilimab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06558227
- Phase: 2
- Setting: A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06558227: https://clinicaltrials.gov/study/NCT06558227

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06558227.json